KEGG   ORTHOLOGY: K06621
Entry
K06621                      KO                                     

Symbol
CDKN2A, P16, INK4A
Name
cyclin-dependent kinase inhibitor 2A
Pathway
map01522  Endocrine resistance
map01524  Platinum drug resistance
map04110  Cell cycle
map04115  p53 signaling pathway
map04218  Cellular senescence
map04934  Cushing syndrome
map05163  Human cytomegalovirus infection
map05166  Human T-cell leukemia virus 1 infection
map05200  Pathways in cancer
map05203  Viral carcinogenesis
map05206  MicroRNAs in cancer
map05212  Pancreatic cancer
map05214  Glioma
map05218  Melanoma
map05219  Bladder cancer
map05220  Chronic myeloid leukemia
map05223  Non-small cell lung cancer
map05225  Hepatocellular carcinoma
Disease
H00004  Chronic myeloid leukemia
H00008  Burkitt lymphoma
H00009  Adult T-cell leukemia
H00014  Non-small cell lung cancer
H00015  Malignant pleural mesothelioma
H00016  Oral cancer
H00017  Esophageal cancer
H00019  Pancreatic cancer
H00022  Bladder cancer
H00025  Penile cancer
H00036  Osteosarcoma
H00038  Melanoma
H00040  Squamous cell carcinoma
H00042  Glioma
H00046  Cholangiocarcinoma
H00047  Gallbladder cancer
H00048  Hepatocellular carcinoma
H00054  Nasopharyngeal cancer
H00055  Laryngeal cancer
H00409  Type 2 diabetes mellitus
H01463  Mycosis fungoides
H01464  Mantle cell lymphoma
H01508  Salivary gland cancer
H01509  Tonsillar cancer
H01513  Retinoblastoma
H01556  Meningioma
H02424  Primary central nervous system lymphoma
H02434  Diffuse large B-cell lymphoma, not otherwise specified
Brite
KEGG Orthology (KO) [BR:ko00001]
 09140 Cellular Processes
  09143 Cell growth and death
   04110 Cell cycle
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   04115 p53 signaling pathway
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   04218 Cellular senescence
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05206 MicroRNAs in cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05203 Viral carcinogenesis
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09162 Cancer: specific types
   05212 Pancreatic cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05225 Hepatocellular carcinoma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05214 Glioma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05220 Chronic myeloid leukemia
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05218 Melanoma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05219 Bladder cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05223 Non-small cell lung cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09172 Infectious disease: viral
   05166 Human T-cell leukemia virus 1 infection
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05163 Human cytomegalovirus infection
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09167 Endocrine and metabolic disease
   04934 Cushing syndrome
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09176 Drug resistance: antineoplastic
   01524 Platinum drug resistance
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   01522 Endocrine resistance
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
Other DBs
GO: 0004861
Genes
HSA: 1029(CDKN2A)
PTR: 465021(CDKN2A)
PPS: 100975637(CDKN2A)
GGO: 101145463(CDKN2A)
PON: 100461015
NLE: 100586796(CDKN2A)
MCC: 709988
MCF: 102135474(CDKN2A)
CSAB: 103219354
CATY: 105591311 105591312
RRO: 104654275(CDKN2A)
RBB: 108537054(CDKN2A)
TFN: 117098660(CDKN2A)
CJC: 100394189(CDKN2A)
SBQ: 101038444
MMUR: 105874194
MMU: 12578(Cdkn2a)
MCAL: 110293174
MPAH: 110323545
RNO: 25163(Cdkn2a)
MCOC: 116096224
MUN: 110554386
CGE: 100764983
PLEU: 114698355
NGI: 103730663
CCAN: 109701107
OCU: 100340625(CDKN2A)
VVP: 112911644(CDKN2A)
VLG: 121495863
AML: 100472171
UAH: 113260575
ELK: 111159871
MPUF: 101672555(CDKN2A)
EJU: 114218214
MLX: 118018235
FCA: 101089220(CDKN2A)
PYU: 121034522
PBG: 122475137
AJU: 106986386
HHV: 120223233(CDKN2A)
BTA: 616369(CDKN2A)
BOM: 102284461(CDKN2A)
BIU: 109562627
BBUB: 102406311
CHX: 108636541
OAS: 114113021
ODA: 120862141
CCAD: 122452871
CDK: 105092872
BACU: 103012968(CDKN2A)
LVE: 103072667(CDKN2A)
OOR: 101276268(CDKN2A)
DLE: 111163175
PCAD: 102984840
ECB: 100146270
EAI: 106824796
MYB: 102260311(CDKN2A)
MMYO: 118667589
HAI: 109374675
SHON: 118984061(CDKN2A)
AJM: 119065840(CDKN2A)
MMF: 118629860
PALE: 102896422
PGIG: 120617114
RAY: 107506789
TOD: 119231948
LAV: 104845647
TMU: 101345867
MDO: 554242(CDKN2A)
PCW: 110201193
OAA: 100083932
 » show all
Reference
PMID:8259215
  Authors
Serrano M, Hannon GJ, Beach D
  Title
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
  Journal
Nature 366:704-7 (1993)
DOI:10.1038/366704a0
  Sequence
[hsa:1029]
Reference
PMID:9724636
  Authors
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G
  Title
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
  Journal
EMBO J 17:5001-14 (1998)
DOI:10.1093/emboj/17.17.5001
  Sequence
[hsa:1029]

DBGET integrated database retrieval system